

## Literaturangaben zu Rundbrief Nr. 16

1. Schlenk RF, Ganser A, Döhner K. Prognostic and Predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia. *ASCO Educational Book*. 2010;228-232.
2. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010;115:453-474.
3. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *J Clin Oncol*. 2009;27(35):6041-6051.
4. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. Wiley: New York. 1980;167-171.
5. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. *Leukemia*. 2011;25(9):1433-1438.
6. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. *The Annals of statistics*. 1988;16(3):1141-1154.
7. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. *Blood*. 2011;118(3):686-692.
8. Safaian NN, Czibere A, Bruns I, et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. *Leuk Res*. 2009;33:348-350.
9. Metzelder S, Wang Y, Wollmer E et al. Compassionate use of sorafenib in FLT3-ITD positive acute myeloid leukemia: sustained regression before and after allogenic stem cell transplantation. *Blood*. 2009;113:6567-6571.
10. Winkler J, Rech D, Kallert S et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. *Leuk Res*. 2010;34:e270-e272.
11. Metzelder, ASH 2010, Abstract #3314.
12. Elwyn G, Seagrove A, Thorne K, Cheung WY. Ethics and research governance in a multicentre study: add 150 days to your study protocol. *BMJ*. 2005;330(7495):847.
13. Frewer LJ, Coles D, Champion K, et al. Has the European Clinical Trials Directive been a success? *BMJ*. 2010;340:c1862.
14. Hackshaw A, Farrant H, Bulley S, Seckl MJ, Ledermann JA. Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study. *J R Soc Med*. 2008;101(6):299-304.
15. Hearn J, Sullivan R. The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK. *Eur J Cancer*. 2007;43(1):8-13.
16. Hemminki A, Kellokumpu-Lehtinen PL. Harmful impact of EU clinical trials directive. *BMJ*. 2006;332(7540):501-502.
17. Tyndall A. Why do we need noncommercial, investigator-initiated clinical trials? *Nat Clin Pract Rheumatol*. 2008;4(7):354-355.